Ruxolitinib for Cancer Cachexia

NCT04906746 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Stage IV Non-small Cell Lung Cancer
Cachexia

Interventions

DRUG: Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.

Sponsor

Tu Dan

Collaborators

[object Object]